Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) FCF Margin (2023 - 2025)

Immunome's FCF Margin history spans 3 years, with the latest figure at 1247.72% for Q2 2025.

  • For Q2 2025, FCF Margin fell 29726.0% year-over-year to 1247.72%; the TTM value through Dec 2025 reached 2765.09%, down 150859.0%, while the annual FY2025 figure was 2765.09%, 150859.0% down from the prior year.
  • FCF Margin reached 1247.72% in Q2 2025 per IMNM's latest filing, up from 1833.46% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1018.06% in Q1 2023 to a low of 1833.46% in Q1 2025.
  • Average FCF Margin over 3 years is 791.64%, with a median of 1050.35% recorded in 2024.
  • Peak YoY movement for FCF Margin: crashed -231388bps in 2024, then tumbled -29726bps in 2025.
  • A 3-year view of FCF Margin shows it stood at 453.45% in 2023, then tumbled by -257bps to 1618.88% in 2024, then rose by 23bps to 1247.72% in 2025.
  • Per Business Quant, the three most recent readings for IMNM's FCF Margin are 1247.72% (Q2 2025), 1833.46% (Q1 2025), and 1618.88% (Q4 2024).